Shockwave Therapy for ED: What the Evidence Says

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·11 min read

Low-intensity extracorporeal shockwave therapy sits in an unusual position in sexual medicine: it is genuinely promising, biologically plausible, and aggressively marketed — often well ahead of what the evidence can support. For clinicians, the value of understanding it lies precisely in being able to separate the regenerative science from the energy-based sales pitch. This guide situates shockwave within the broader field of sexual health and dysfunction and is written to be evidence-honest about where it stands today.

This is clinical education for providers, not medical advice, and nothing here is a treatment recommendation, protocol, or substitute for current device labeling and the published literature.

What is shockwave therapy?

Shockwave therapy for erectile dysfunction is a non-invasive, energy-based treatment. As Dr. Greenleaf describes it in Empire's course, the treatment “involves using a wand-like device that emits gentle, high-energy sound waves or shock waves to targeted areas of the penis.” It is performed without anesthesia, and a single session typically takes around 15 to 20 minutes.

The technical term is low-intensity extracorporeal shockwave therapy (often abbreviated LiSWT or Li-ESWT). “Extracorporeal” simply means the energy is generated outside the body and transmitted through the skin — the same broad family of acoustic-pulse technology that has long been used to break up kidney stones, but here delivered at much lower energy with a regenerative rather than destructive intent.

That regenerative premise is the heart of the rationale. The proposed mechanism is that controlled mechanical stress on the tissue triggers angiogenesis and neovascularization — the growth of new blood vessels — alongside tissue remodeling. Because the vast majority of erectile dysfunction is fundamentally a vascular problem, a therapy that aims to rebuild penile blood supply at the tissue level is a genuinely interesting idea. The question is whether the biology translates into reliable clinical benefit.

How it is claimed to work

To understand the claim, it helps to recall the normal physiology. An erection is a vascular event: sexual stimulation triggers the release of nitric oxide, which relaxes the smooth muscle in the penile arteries and sinusoids, allowing blood to flow in and engorge the corpora cavernosa. When that vascular machinery is impaired — by diabetes, cardiovascular disease, or age-related decline — blood flow falls and erections weaken.

Shockwave therapy is claimed to intervene at exactly this level. Drawing on Dr. Greenleaf's account, the proposed mechanisms are:

• Angiogenesis (new vessel growth). The acoustic pulses are thought to trigger the release of angiogenic factors that promote the growth of new blood vessels in the penis, increasing the vascular bed available to carry blood during arousal.
• Tissue remodeling. The shock waves are proposed to stimulate tissue repair, potentially reversing some of the structural changes in penile blood vessels and tissue that contribute to ED.
• Nitric oxide production. Shockwave therapy has been shown to increase nitric oxide production — the key molecule mediating the vasodilation that underlies an erection.

It is worth pausing on what distinguishes shockwave from the standard pharmacologic approach. A PDE5 inhibitor such as sildenafil acts on demand: it amplifies an existing nitric-oxide signal each time it is taken, but it does nothing to change the underlying tissue. Shockwave's regenerative pitch is the opposite — a course of treatment intended to restore the tissue itself, with the hope of a more durable effect. That is the appeal. Whether it delivers is an evidence question, not a mechanism question.

What the evidence actually shows

Here is where honesty matters most. The plausible biology has, predictably, run ahead of the clinical proof, and the marketing has run further still. The accurate summary is that shockwave is promising but still emerging — encouraging signals, not settled science.

The reviewed literature shows a trend toward positive improvement in erectile function with shockwave therapy. But that signal comes with real caveats, and Dr. Greenleaf is explicit about them in the course: “the quality of evidence is still debated.” Studies are heterogeneous, sample sizes are often small, and there is no agreed-upon optimal treatment protocol — trials vary in the number of shocks per session, where on the anatomy they are delivered, and how many sessions are given, making it genuinely hard to compare results across studies or to say which protocol works.

A frequent point of confusion is radial versus focused shockwaves. Focused devices deliver higher-energy waves that penetrate deeper into the tissue; radial devices use lower-energy waves with a more superficial effect. The comparative data are mixed: one retrospective study found no significant difference in symptom-score improvement between the two, while another reported a higher rate of clinically meaningful improvement with radial than focused. As the course puts it, “both radial and focus have shown promise for treating ED, but the comparative efficacy between the two approaches is still unclear.” A randomized, sham-controlled trial at the Cleveland Clinic is underway to compare radial, focused, and sham therapy directly — the kind of rigorous head-to-head data the field still lacks.

The most important guardrail is the position of the specialty societies. As Dr. Greenleaf notes, the Sexual Medicine Society of North America recommends that shockwave therapy be used only under strict research protocols, because more robust clinical-trial data are still needed before it can be endorsed for routine clinical use. That is the evidence-honest bottom line: real promise, genuine biological rationale, but not yet proven enough to be marketed as an established cure.

Who it may suit

If shockwave has a most-plausible candidate, it is the man with mild, vascular ED — the patient whose problem is primarily reduced penile blood flow rather than a neurologic, hormonal, or severe structural cause. The regenerative rationale, restoring vascular supply, lines up best with that population, and it is in milder vascular cases that the published signal is most favorable.

Several groups are correspondingly poor fits. Men whose ED is predominantly psychogenic, hormonal (for example, untreated low testosterone), or neurogenic are unlikely to benefit from a vascular intervention; their care belongs with the underlying cause. Severe, long-standing ED — particularly the post-prostatectomy or advanced-diabetic patient with extensive tissue damage — is a much harder target, and these are the patients more often managed with injections, vacuum devices, or implants.

Because ED is so frequently a vascular warning sign, candidate selection is also a clinical-safety opportunity. Dr. Greenleaf is emphatic that ED can be “the canary in the coal mine” for underlying cardiovascular disease, often preceding overt heart disease by years. A proper workup — including consideration of cardiovascular risk and, where relevant, hormones — should always come before any regenerative procedure. Shockwave is never a reason to skip that evaluation.

Safety and tolerability

On the safety question, the news is reassuring, and it is one of the genuine strengths of the modality. Across the reviewed studies, both radial and focused shockwave therapy appear to be low-risk, with no major adverse events reported. Shockwave is, in Dr. Greenleaf's summary, “a low-risk treatment, with few reported side effects.”

The side effects that do occur are minor and transient. The main one noted in trials is mild treatment-related discomfort during the session, which is generally easily managed. Because the treatment is non-invasive and performed without anesthesia, it avoids the injection-site risks — bruising, fibrosis, the possibility of priapism — that accompany intracavernosal therapies.

The honest framing, then, is that the principal risk of shockwave for ED is not physical harm but disappointed expectations. A low-risk profile is a real advantage, but low risk is not the same as proven benefit, and a favorable safety record should never be used to imply efficacy the data have not established.

The business and regulatory reality

No honest discussion of shockwave for ED is complete without the commercial context, because it shapes how the treatment is sold. Shockwave is almost always a cash-pay service — not covered by insurance — delivered as a multi-session package across roughly four to twelve visits. That economic model creates a strong incentive to promote it, and the marketing has frequently outpaced the science.

The regulatory facts must lead. Low-intensity shockwave therapy is not FDA-cleared for the treatment of erectile dysfunction. Some devices carry clearance for other indications and are used off-label for ED; some, as Dr. Greenleaf notes, are positioned as in-office systems while others — the Phoenix is one example she cites — are home devices that a practice can sell to patients. None of that adds up to an ED indication. Branded, trademarked energy-based treatments marketed under proprietary names should be understood for what they are: marketing wrappers around the same investigational technology, not a separate, more proven therapy.

For providers, this translates into a short list of claims to avoid:

• Do not call it “FDA-approved” or “FDA-cleared” for ED — it is neither.
• Do not present it as a guaranteed or permanent cure; the durability data are not there.
• Do not imply it is superior to established treatments such as PDE5 inhibitors without evidence.
• Do disclose plainly that it is investigational and that the strongest professional guidance is to use it under research protocols.

Offered transparently — honest about the evidence, honest about the regulatory status, with realistic expectations set before the first session — shockwave can be a legitimate part of a practice. Offered with inflated claims, it becomes both a clinical and a compliance liability.

Where it fits vs other options

Placed honestly within the treatment landscape, shockwave is best understood as an emerging adjunct, not a first-line therapy. The established, evidence-backed starting point for most men remains the oral PDE5 inhibitors — sildenafil, tadalafil, and the rest — supported by lifestyle measures that Dr. Greenleaf stresses can themselves improve erectile function meaningfully. For men who do not respond to or cannot take oral medication, injectable therapies, vacuum devices, and implants are the proven next steps.

Shockwave occupies a different niche: the regenerative tier, alongside PRP for sexual health — both biologically interesting, both still emerging, both honestly described as investigational with limited high-quality evidence. They appeal to the patient seeking to improve the underlying tissue rather than rely on an on-demand drug, and to the patient with milder vascular ED who has not been satisfied with, or wishes to reduce reliance on, pills. That is a real and reasonable patient interest. It simply has to be met with candor about what the science can and cannot yet promise.

Provider training

The hardest skill in offering shockwave is not operating the device — it is exercising evidence-honest judgment: selecting the right candidate, distinguishing the biology from the marketing, knowing the investigational and regulatory status cold, and setting expectations a patient can trust. That judgment is what separates a credible regenerative practice from a high-pressure one.

Empire's curriculum is built around exactly this. Taught by Dr. Betsy Greenleaf, DO — board-certified in OB/GYN and urogynecology and Empire's Director of Anti-Aging — the sexual dysfunction training situates shockwave within the full workup of ED, the vascular and cardiovascular context, and the realistic comparison against PDE5 inhibitors, injectables, devices, and PRP, so providers can offer it responsibly and lawfully.